Despite a net loss, Hyperfine Inc reports a 25% revenue increase and strategic expansions in Q1 2024.
Despite a challenging quarter, AVITA Medical Inc (AVHHL) reaffirms full-year revenue guidance and progresses on strategic initiatives.
Unveiling key financial outcomes and strategic milestones, Capricor Therapeutics sets a robust path for 2024.